Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification
Biology,
Год журнала:
2024,
Номер
13(10), С. 762 - 762
Опубликована: Сен. 25, 2024
Prostate
cancer
remains
a
significant
health
challenge,
being
the
most
prevalent
non-cutaneous
in
men
worldwide.
This
review
discusses
critical
advancements
biomarker
discovery
using
single-omics
and
multi-omics
approaches.
Multi-omics,
integrating
genomic,
transcriptomic,
proteomic,
metabolomic,
epigenomic
data,
offers
comprehensive
understanding
of
molecular
heterogeneity
prostate
cancer,
leading
to
identification
novel
biomarkers
therapeutic
targets.
holistic
approach
not
only
enhances
specificity
sensitivity
detection
but
also
supports
development
personalized
treatment
strategies.
Key
studies
highlighted
include
genes,
genetic
mutations,
peptides,
metabolites,
potential
through
analyses,
which
have
shown
promise
improving
management.
The
integration
clinical
practice
can
potentially
revolutionize
prognosis
treatment,
paving
way
for
precision
medicine.
underscores
importance
continued
research
application
overcome
current
challenges
diagnosis
therapy.
Язык: Английский
Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge
Biomedicines,
Год журнала:
2024,
Номер
12(12), С. 2742 - 2742
Опубликована: Ноя. 29, 2024
Background:
The
treatment
landscape
for
non-small
cell
lung
cancer
(NSCLC)
has
evolved
significantly
with
the
advent
of
immunotherapy.
Nonetheless,
uncertainty
regarding
optimal
first-line
treatments,
special
populations,
and
feasibility
rechallenge
remains.
This
study
aims
to
investigate
Italian
oncologists’
opinions
on
these
aspects
through
a
Delphi
Survey.
Methods:
A
steering
committee
(SC)
six
oncologists
identified
three
topics
interest,
namely
NSCLC
(first
line)
therapeutic
choice,
immunotherapy
rechallenge),
drafted
several
topic-related
statements
be
voted
in
Survey
by
61
forming
Panel.
survey
included
two
rounds,
wherein
experts
rated
their
agreement/disagreement
5-point
Likert
scale.
Consensus
was
defined
as
at
least
75%
panel.
Results:
SC
69
first
round,
which
16
(23.2%)
met
agreement
threshold,
5
(7.2%)
disagreement
48
(69.6%)
did
not
reach
consensus.
revised
latter
37
second
round.
Overall,
(13.5%)
1
(2.7%)
31
(83.8%)
consensus
Conclusions:
showed
necessity
molecular
characterization,
mutations,
smoke,
role
steroid
therapy,
rechallenge,
revealed
areas
among
use
NSCLC.
Statements—where
met—can
used
guide
future
clinical
research
resolving
issues.
Язык: Английский